Literature DB >> 3178486

Lymphocyte phenotype and function changes in burn patients after intravenous IgG therapy.

D G Burleson1, A D Mason, A T McManus, B A Pruitt.   

Abstract

The effects of prophylactic administration of intravenous IgG on immune-cell phenotype and function in burn patients were compared with those of patients receiving standard therapy. Intravenous IgG infusions were given twice weekly for three weeks postburn or until wound closure. Intravenous IgG had no effect on the proportion of total T-lymphocytes, T-helper lymphocytes, or T-suppressor lymphocytes, but the proportion of B-lymphocytes decreased 40% in treated patient samples. Lymphocytes from treated patients incorporated less thymidine when stimulated with concanavalin A or pokeweed mitogen, but not with phytohemagglutinin. The amount of IgM secreted by pokeweed mitogen-stimulated cultures from treated patients increased by 24%, while the amount of IgG remained constant. The changes in beta-lymphocyte number and functional response may have been induced by the increased serum IgG levels in the intravenous IgG-treated patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3178486     DOI: 10.1001/archsurg.1988.01400350093014

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  The renaissance man of burn surgery: Basil A. Pruitt, Jr.

Authors:  Karel D Capek; Guillermo Foncerrada; R Patrick Clayton; Michaela Sljivich; Charles D Voigt; Gabriel Hundeshagen; Janos Cambiaso-Daniel; Craig Porter; Ashley Guillory; David N Herndon
Journal:  J Trauma Acute Care Surg       Date:  2017-11       Impact factor: 3.313

2.  Endotoxin, cellular immune dysfunction and acute pancreatitis.

Authors:  P J Curley
Journal:  Ann R Coll Surg Engl       Date:  1996-11       Impact factor: 1.891

3.  Increased oxidative phosphorylation in lymphocytes does not atone for decreased cell numbers after burn injury.

Authors:  Tony Chao; Belinda I Gomez; Tiffany C Heard; Michael A Dubick; David M Burmeister
Journal:  Innate Immun       Date:  2020-01-06       Impact factor: 2.680

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.